

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

RESULTS OF ANNUAL GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the notice of AGM dated 31 March 2016 were duly passed at the AGM held on 24 May 2016.

RESULTS OF THE AGM

Reference is made to the notice of an annual general meeting (the “AGM”) of the Company (the “Notice”) dated 31 March 2016. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Notice. The board of directors of the Company is pleased to announce that all the resolutions as set out in the Notice were duly passed by way of poll at the AGM held on 24 May 2016.

As at the date of the AGM, the Company had 1,595,000,000 shares in issue including 697,500,000 domestic shares and 897,500,000 H shares. Shareholders of the Company holding a total of 1,571,999,500 shares of the Company were entitled to attend and vote for or against all the ordinary resolutions set out in the Notice by way of poll at the AGM. There were no shares entitling the shareholders of the Company to attend and vote only against any of the ordinary resolutions at the AGM.

Details of the poll result in respect of ordinary resolutions proposed at the AGM were as follows:

| Ordinary Resolutions | | Number of Shares Represented by Votes (%) | | Total Number of Shares |
|----------------------|--|---|----------------|------------------------|
| | | For | Against | |
| 1. | To consider and, if thought fit, approve the audited consolidated financial statement of the Group for the year ended 31 December 2015. | 1,571,999,500 shares 100% | 0 shares 0% | 1,571,999,500 shares |
| 2. | To consider and, if thought fit, approve the report of the directors of the Company. | 1,571,999,500 shares 100% | 0 shares 0% | 1,571,999,500 shares |
| 3. | To consider and, if thought fit, approve the report of the Supervisory Committee of the Company. | 1,571,999,500 shares 100% | 0 shares 0% | 1,571,999,500 shares |
| 4. | To consider and, if thought fit, approve the proposal of appointing BDO Limited as auditor of the Company for the financial year of 2016 and authorize the Directors of the Company to fix their remuneration. | 1,571,999,500 shares 100% | 0 shares 0% | 1,571,999,500 shares |

Tianjin Zhong Yue CPA Firm (天津中悅會計師事務所), an independent external accountants firm acted as the scrutineer for the purpose of vote-taking at the AGM.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
24 May 2016

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Wang Shuxin; the non-executive Directors of the Company are Feng Enqing, Chen Yingzhong and Ou Linfeng; the independent non-executive Directors of the Company are Guan Tong, Wu Chen and Peter K.S. Chan.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

The announcement will remain at the “Latest Company Announcements” page on the GEM website at www.hkgem.com for at least seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.